This Letter of Intent (“LOI”) sets out the basic understanding between H. Lundbeck A/S (“Lundbeck”) and International Health Partners Ltd (“IHP”) regarding a partnership agreement (“Partnership Agreement”) to be negotiated, and – if acceptable to both parties – to be executed and entered into covering the period of 2022 to 2025.

For the avoidance of doubt, the commitments described below are subject to contract and are not legally binding for Lundbeck or IHP.

Mission statement

Mental health is an area with massive unmet needs, widespread stigmatization, and a lack of funding compared to other healthcare areas. Access to treatment and services for mental health is an element of healthcare provision which is often overlooked and unequal in who it serves.

Medical product donations continue to play an important role for many diseases that affect populations living in low and middle-income countries, and for people living in poverty, it may represent the only chance they have to access the treatment they need.

UK based health charity, IHP and Denmark-based, global pharmaceutical company, Lundbeck, have come together to help address these issues. The collaboration will aim to improve the access to medicine of people in low and middle-income countries and provide vital medication for people affected by brain diseases, who would otherwise have no access to this kind of treatment.

The partnership will see Lundbeck donate mental health related medicine to IHP as well as financial funding to cover operational costs. IHP will coordinate the safe transport of medicine to, and placement with, its network of in-country NGO partners, to deliver targeted programmes in the Middle East and Africa.

This partnership will also contribute in addressing the unmet mental health needs in these regions as well as raising awareness of mental health conditions, fighting stigma, advocating for parity for mental health and ultimately serving the people often overlooked in mental health provision.

1. Scope

Building on an initial pilot donation programme in 2021, Lundbeck and IHP will over the next four years, seek to broaden the scope of the donation programme within low and middle-income countries in the Middle East and Africa. The partnership will aim to increase access to mental health medicine for vulnerable communities in these areas, including refugee populations and those affected by natural or manmade disasters. Lundbeck’s intention is to gradually increase product donations and financial funding, as well as to expand the number of in-country NGO partners and distribution countries.
1.1. Funding

To ensure the success of this programme, subject to contract, Lundbeck intends to support IHP through financial funding. This funding will cover IHP’s operational costs, to ensure that the high standards required for the delivery of this programme are maintained and will cover monitoring and evaluation support for IHP’s in-country NGO partners when implementing the programme.

2. Due Diligence

Patient safety will be of the utmost importance and priority of this partnership and is a condition for any donation to be made by Lundbeck. In order to ensure this, Lundbeck and IHP will carry out regular risk-based due diligence assessments and audits of in-country NGO partners and provide training and capacity building for those delivering the programme.

3. Communications

To raise awareness and fight stigma surrounding mental health conditions, communication will be a key aspect of this partnership. To help convey the barriers to access people in these regions face, IHP and its in-country NGO partners will gather and tell the stories of patients receiving treatment and healthcare workers administering care as part of the programme.

Both IHP and Lundbeck commit to sharing these stories and using their platforms, always ensuring compliance with any applicable laws and regulations, to advocate for better parity in mental health provision in the region.

Adele Paterson  
CEO, IHP  
December 2021

Deborah Dunsire  
CEO, Lundbeck  
December 2021